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Objective: The Siewert classification system differentiates between adenocarcinoma of the gastroesophageal
junction and that of the distal esophagus. The purpose of this study was to evaluate whether there were differences
in the location and prevalence of lymph node metastases, type of recurrence, and survival with these tumors that
warrant distinguishing between them in clinical practice.
Methods: Records of all patients who underwent resection for adenocarcinoma of the distal esophagus or
gastroesophageal junction from 1987 to 2007 were retrospectively reviewed. Based on the endoscopic location
of the epicenter of the tumor in relation to the gastroesophageal junction, tumors were categorized in 301 patients
as being of the distal esophagus and in 208 as being of the gastroesophageal junction.
Results: There were no significant differences in age, sex, or body mass index between patients with adenocar-
cinoma of the distal esophagus or gastroesophageal junction. Patients with adenocarcinoma of the distal esoph-
agus were more likely to have reflux symptoms (75% vs 53%, P< .0001) and peritumoral intestinal metaplasia
(73% vs 51%, P<.0001) and be in a surveillance program (54% vs 9%, P¼ .0005) compared with patients with
adenocarcinoma of the gastroesophageal junction. However, the prevalence and location of nodal metastases was
similar, and in node-positive patients mediastinal node involvement was present in more than 40% of the patients
in each group (distal esophageal adenocarcinoma, 47%; gastroesophageal junction adenocarcinoma, 41%).
Survival was similar (5 years: distal esophageal adenocarcinoma, 45%; gastroesophageal junction adenocarci-
noma, 38%; P ¼ .14), as was the prevalence and type of recurrence.
Conclusion: The prevalence and distribution of lymph node metastases in patients with adenocarcinoma of the
distal esophagus and gastroesophageal junction were similar, and after esophagectomy, there was no difference in
overall survival or recurrence. Efforts to differentiate between these tumors are unnecessary, and both are
effectively treated with esophagectomy.Earn CME credits at
http://cme.ctsnetjournals.org
The gastroesophageal junction (GEJ) represents the border be-
tween the esophagus and the stomach. Its perceived location
differs based on whether external anatomic landmarks, endo-
scopic landmarks, or histology are used.1 Tumors at the GEJ
are predominantly adenocarcinomas, and like adenocarcinoma
of the distal esophagus (DE), the incidence of this cancer has
been increasing rapidly over the past 2 decades in the Western
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doi:10.1016/j.jtcvs.2009.05.039594 The Journal of Thoracic and Cardiovascular Surworld.2 However, controversy and confusion persist regarding
the location of the GEJ and the causes of tumors in this area.
In an effort to clarify some of the confusion and allow
comparison of the results of treatment at different centers,
Siewert and Stein3 introduced a system in which adenocar-
cinomas of the DE and proximal stomach were classified
into 3 types based on the relationship of the epicenter of
the tumor to the endoscopic location of the GEJ. Tumors
with an epicenter 2 to 5 cm above the GEJ were considered
type I or DE tumors, those within 2 cm (above or below) of
the GEJ were type II or true GEJ tumors, and those with an
epicenter 2 to 5 cm distal to the GEJ were type III or subcar-
dial tumors (proximal gastric cancer). This classification
system requires that the GEJ can be localized endoscopi-
cally, which can be difficult with large tumors, and implies
that these cancers can be neatly categorized into those above,
below, or at the GEJ. Furthermore, this classification system
has been used to guide the selection of the surgical approach
for tumors at different locations based on the belief that these
tumors represent distinct clinical entities with different
patterns of lymphatic spread and clinical outcome.4 Type Igery c September 2009
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DE ¼ distal esophagus
GEJ ¼ gastroesophageal junction
tumors, which are considered esophageal in origin, are typ-
ically treated by means of an esophagectomy with abdomi-
nal and lower mediastinal node dissection. Type III
tumors, which are considered to represent true gastric can-
cers, are typically treated with gastrectomy and resection
of the regional abdominal lymph nodes. The management
of type II (or GEJ) tumors remains less clear, with the debate
centered on whether these are best treated like proximal
gastric cancer or DE cancer. In addition, the location of
potentially involved lymph nodes and the extent of lympha-
denectomy necessary to adequately treat GEJ tumors remain
disputed. Therefore the purpose of this study was to compare
the prevalence and distribution of lymph node metastases,
the prevalence and type of recurrence, and survival in
patients with adenocarcinoma of the GEJ versus adenocarci-
noma of the DE with the goal of determining whether an
effort to distinguish between these tumors is warranted in
clinical practice.
MATERIALS AND METHODS
We retrospectively reviewed the records of 613 patients who underwent
resection for adenocarcinomawithin 5 cm above or below the GEJ from Jan-
uary 1987 to June 2007. All patients had a preoperative upper endoscopy by
a surgeon in the thoracic/foregut division, and during the endoscopy, the
proximal and distal extents of the tumor and the location of the GEJ were
noted. Assessment of the distal extent of the tumor included a retroflexed
view to determine the degree of tumor extension below the GEJ. The GEJ
was defined as the site where the proximal gastric rugal folds met the tubular
esophagus with the stomach decompressed. The endoscopy report was used
to retrospectively categorize tumors based on the Siewert classification sys-
tem. Specifically, when the epicenter of the tumor was located 2 to 5 cm
above the top of the gastric rugal folds, it was classified as a DE tumor,
and when the epicenter was within 2 cm above or below the top of the gastric
rugal folds, the tumor was classified as a GEJ tumor. By using this strategy,
there were 301 patients with Siewert type I (or DE) adenocarcinoma and 208
with Siewert type II (or GEJ) adenocarcinoma. In 8 patients the tumor was
classified as a proximal gastric cancer (Siewert Type III), and these patients
were excluded. In 96 patients the size of the tumor precluded precise clas-
sification, and these patients were analyzed separately as an unclassified
group. The study was approved by the Institutional Review Board of the
Keck School of Medicine at the University of Southern California.
Preoperative evaluation included a detailed history focusing on the
presence of reflux symptoms, standard laboratory tests, and a computed to-
mographic scan of the chest and abdomen. Endoscopic ultrasonographic
analysis and positron emission tomographic scans were obtained later in
this series as these tests became available. Neoadjuvant therapy was used
selectively based on the local–regional extent of disease.
Surgical Approach
The operative approach was determined by the surgeon based on the
location of the tumor, the patient’s cardiopulmonary status, comorbid condi-The Journal of Thoracic and Ctions, and the local–regional extent of disease. Our standard approach was an
en bloc resection with 2-field lymphadenectomy. In some patients with intra-
mucosal tumors, a vagal-sparing esophagectomy was performed, whereas
a transhiatal or minimally invasive approach was used in patients with signif-
icant comorbid conditions or advanced age. A few patients with early GEJ tu-
mors were treated with gastrectomy and a D2 lymph node dissection. The
techniques for these procedures have been previously reported.2,5,6
Histopathologic Assessment
Hematoxylin and eosin–stained slides of paraffin-embedded tissue were
used to determine tumor depth and the presence of lymph node metastases.
Tumors were pathologically staged according to the TNM criteria for the
esophagus by using the 6th edition of theCancer Staging Manual published
by the American Joint Committee on Cancer. Coexisting Barrett’s
esophagus was defined by the presence of intestinal metaplasia separate
from the tumor mass either on preoperative endoscopic biopsy or in the
surgical specimen.
Follow-up
All patients were routinely seen in the outpatient clinic after resection at
intervals of 3 months for the first 3 years and every 6 months thereafter until
5 years. Beyond 5 years, follow-up visits were on an annual basis. Each visit
included routine blood work and a computed tomographic scan of the chest
and abdomen. Positron emission tomographic scans, once available, were
obtained annually. Recurrent disease was diagnosed based on clinical, endo-
scopic, and/or radiographic findings, and histologic confirmation was
sought when possible. Recurrence was classified as local–regional (occur-
ring in the upper abdomen or mediastinum), distant (including all lymph
node stations outside the lymphadenectomy field), and systemic (solid
organ metastases). Follow-up was complete in 469 (92%) of 509 patients
until December 2007 or death.
Statistical Analysis
Data are presented as means unless otherwise noted. Proportions were
compared by using Fisher’s exact test, and means were compared by using
the 2-sample Student’s t test or Mann–Whitney rank sum test. All-cause
mortality and disease-specific survival curves were plotted by using the
Kaplan–Meier method and compared by using the log-rank test. Univariate
analysis was performed to identify factors that were different between pa-
tients with DE and GEJ tumors. Factors that were significantly different
on univariate analysis were entered as covariates into a Cox regression anal-
ysis to compare survival and recurrence in patients with DE or GEJ adeno-
carcinoma adjusted for covariates.
RESULTS
Demographic information, type of resection, and patho-
logic findings in the 509 patients are shown in Table 1. There
were no significant differences in age, sex, or body mass in-
dex among patients with DE and GEJ tumors. Patients with
DE adenocarcinoma were significantly more likely to have
reflux symptoms and Barrett’s esophagus and were more
likely to have their tumors detected within a surveillance
program compared with patients with GEJ adenocarcinoma.
There were no significant differences in the median tumor
length, type of resection, or use of neoadjuvant therapy.
The TNM characteristics of the tumors are compared in
Table 2. There was a higher prevalence of intramucosal
tumors in the DE group compared with the GEJ group, likely
related to the greater prevalence of surveillance endoscopy
in the DE group. Correspondingly, there were moreardiovascular Surgery c Volume 138, Number 3 595
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group: 53% vs DE group: 43%, P ¼ .06). The prevalence
of lymph node metastases and the number of involved
lymph nodes was similar in patients with DE or GEJ adeno-
carcinoma. Table 3 shows the prevalence of lymph node in-
volvement based on the depth of tumor invasion for both
tumor locations. There was no significant difference in the
prevalence of systemic disease found at the time of the oper-
ation or the completeness of resection. Greater than 90% of
patients in both groups had an R0 resection.
There were 96 patients with adenocarcinomas too large or
bulky to clearly assign to either the DE or GEJ group. The
prevalence of a transmural tumor was significantly higher
in this group (unclassified group: 69% vs DE groupþGEJ
group: 47%, P ¼ .0005), and significantly fewer patients
in this group were node negative (unclassified group: 31%
vs DE groupþGEJ group: 47%, P ¼ .004). Furthermore,
patients with unclassified tumors had worse 5-year survival
(unclassified group: 25% vs DE groupþGEJ group: 42%;
P ¼ .02, log-rank test).
To accurately assess and compare the distribution of lymph
node metastases in patients with DE and GEJ tumors, we an-
alyzed only those patients who had a systematic thoracic and
TABLE 1. Patient and tumor characteristics
DE tumors
(n ¼ 301)
GEJ tumors
(n ¼ 208) P value*
Age in years (SD) 64.6 ( 11.2) 64.3 ( 12.3) .79
Male/female ratio 6.8:1 6.5:1 .67
Body mass
index (SD)
28.9 ( 5.7) 28.5 ( 5.9) .46
History of heartburn or
regurgitation
227 (75.4%) 114 (54.8%) <.0001
Barrett’s surveillance 62 (20.6%) 19 (9.1%) .0005
Presence of dysphagia 162 (53.8%) 115 (55.3%) .79
Presence of intestinal
metaplasia
219 (72.8%) 106 (51.0) <.0001
Neoadjuvant therapy 56 (18.6%) 38 (18.3%) 1.0
Type of resection .69
En bloc
esophagectomy
150 (49.8%) 100 (48.1%)
Transhiatal
esophagectomy
110 (36.5%) 74 (35.6%)
Other types 41 (13.6%) 34 (16.3%)
Vagal-sparing
esophagectomy
24 (8.0%) 14 (6.7%)
Transthoracic
esophagectomy
17 (5.6%) 11 (5.3%)
Total gastrectomy 0 9 (4.3%)
Length of tumor, cm (SD) 3.2 (2.6) 3.4 (2.6) .29
Tumor differentiation
Well 43 (14.3%) 32 (15.4%) .80
Moderate 129 (42.9%) 77 (37.0%) .40
Poor 129 (42.9%) 99 (47.6%) .52
DE, Distal esophageal; GEJ, gastroesophageal junction; SD, standard deviation.
*Mann–Whitney rank sum test for means and 2-sided Fisher’s exact test for propor-
tions.596 The Journal of Thoracic and Cardiovascular Suabdominal lymphadenectomy (en bloc resection) without
neoadjuvant therapy. The prevalence of lymph node involve-
ment at each location is shown in Table 4. The pattern of
lymph node metastases in patients with N1 disease who had
an en bloc esophagectomy is shown in Figure 1. The preva-
lence of node involvement and the distribution of involved
lymph nodes were similar for DE and GEJ tumors. Impor-
tantly, more than 40% of node-positive patients had involved
nodes in the mediastinum whether the tumor was located in
the DE or at the GEJ. In 9% of patients with DE tumors
and 8% of patients with GEJ tumors, a positive mediastinal
node was the only site of lymph node involvement (all re-
sected abdominal lymph nodes were negative).
The median follow-up in surviving patients was 37
months (interquartile range, 8–46 months) and did not differ
between patients with DE and GEJ tumors (38 months and
TABLE 2. TNM classification
DE tumors GEJ tumors P Value*
T classification
No neoadjuvant therapy n ¼ 245 n ¼ 170 .20
T1 (intramucosal) 71 (23.6%) 36 (17.3%)
T1 (submucosal) 38 (12.6%) 26 (12.5%)
T2 30 (10.0%) 18 (8.7%)
T3 104 (34.5%) 82 (39.4%)
T4y 2 (0.7%) 8 (3.8%)
N classification
( neoadjuvant)
n ¼ 301 n ¼ 208
N0 151 (50.2%) 90 (43.3%) .18
N1 150 (49.8%) 118 (56.7%)
No. of nodes involved
1–4 66 (21.9%) 50 (22.1%) .74
5–8 24 (8.0%) 22 (11.1%)
>8 61 (20.3%) 42 (21.1%)
Metastasis M1b 12 (3.9%) 9 (4.5%) .83
Overall stage .52
No neoadjuvant therapy n ¼ 245 n ¼ 170
I 96 (31.9%) 57 (27.4%)
IIa 26 (8.6%) 16 (7.7%)
IIb 25 (8.3%) 15 (7.2%)
III 88 (29.2%) 76 (36.5%)
IV 10 (3.3%) 6 (2.9%)
Neoadjuvant therapy 56 (18.6%) 38 (18.3%) 1.0
Complete pathologic
response
12 (21.4%) 6 (15.8%) .59
R category
R0 278 (92.4%) 193 (92.7%) 1.0
R1/2 23 (7.6%) 15 (7.3%)
Location of
positive margin
Gastric staple line 4 3
Proximal esophageal 4 1
Radial 8 7
Diaphragm 4 2
Other 3 2
DE, Distal esophageal; GEJ, gastroesophageal junction. *Two-sided Fisher’s exact
test or c2 test. yReason for T4: involvement of perigastric fat, diaphragm, pericardium,
or distal pancreas.rgery c September 2009
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was similar for patients with DE and GEJ tumors (Figure 2).
Survival at 5 and 10 years was 45% and 25% for patients
with DE tumors compared with 38% and 31% for patients
with GEJ tumors, respectively. The 5- and 10-year survivals
for both tumor locations considered together are 42% and
27%, respectively. A Cox proportional hazard model was
used to compare survival in patients with GEJ or DE adeno-
carcinoma adjusted for covariates found to be significant on
univariate analysis in Tables 1 and 2 (history of heartburn or
regurgitation, Barrett’s surveillance, and presence of intesti-
nal metaplasia). Cox regression analysis showed no signifi-
cant difference in survival between patients with GEJ
adenocarcinoma and those with DE adenocarcinoma
(adjusted hazard ratio [GEJ vs DE], 1.04; 95% confidence
interval, 0.81–1.34; P ¼ .78).
TABLE 3. The prevalence of lymph node metastases based on tumor
depth of invasion (patients with neoadjuvant therapy excluded)
Depth of
invasion
DE tumors
(n ¼ 245)
GEJ tumors
(n ¼ 172) P value*
Intramucosal 2/71 (2.8%) 1/36 (2.8%) 1.0
Submucosal 11/38 (28.9%) 6/29 (20.7%) .59
Intramural 15/30 (50.0%) 8/16 (50.0%) 1.0
Transmural 96/106 (90.6%) 79/91 (86.8%) .92
DE, Distal esophageal; GEJ, gastroesophageal junction. *Two-sided Fisher’s exact
test.The Journal of Thoracic and CRecurrent cancer was found in 124 (41%) patients with
DE tumors and in 81 (39%) patients with GEJ tumors
(P¼ .65). The type of recurrence was similar for both tumor
locations, with the majority being systemic (Table 5). Carci-
nomatosis was uncommon and not significantly different
between groups (P¼ .13). A Cox proportional hazard model
was used to compare recurrence in patients with GEJ or DE
adenocarcinoma adjusted for covariates found to be
TABLE 4. Prevalence and location of lymph node metastases in
patients who had en bloc resection (all patients not having en bloc
resection were excluded)
DE tumors
(n ¼ 150)
GEJ tumors
(n ¼ 100) P value*
Prevalence of N1 disease 83 (55%) 61 (61%) .43
Location of positive node(s)
Mediastinal 39 (26%) 25 (25%) .88
Paratracheal 3 (2%) 0
Subcarinal 12 (8%) 3 (3%)
Paraesophageal 38 (25%) 25 (25%)
Abdominal 70 (47%) 52 (52%) .44
Parahiatal 33 (22%) 20 (20%)
Perigastric 52 (35%) 45 (45%)
Celiac 9 (6%) 3 (3%)
Other 13 (9%) 8 (8%)
Values are presented as numbers with percentages as shown. DE, Distal esophageal;
GEJ, gastroesophageal junction. *Two-sided Fisher’s exact test.FIGURE 1. The pattern of lymph node involvement in patients with N1 disease after en bloc esophagectomy (n ¼ 144) with distal esophageal (DE) and
gastroesophageal junction (GEJ) tumors.ardiovascular Surgery c Volume 138, Number 3 597
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of heartburn or regurgitation, Barrett’s surveillance, and
presence of intestinal metaplasia). Cox regression analysis
showed no significant difference in recurrence for patients
with GEJ adenocarcinoma or those with DE adenocarci-
noma (adjusted hazard ratio [GEJ vs DE], 0.82; 95% confi-
dence interval, 0.61–1.10; P¼ .19). The majority of patients
who survived beyond 5 years died from a noncancer cause.
DISCUSSION
In contrast to distal gastric cancers, the incidence of ade-
nocarcinoma of both the GEJ and DE has increased dramat-
ically over the past 25 years in the United States.2
Esophageal adenocarcinoma develops secondary to chronic
gastroesophageal reflux disease and Barrett’s esophagus.
FIGURE 2. A, Five-year overall survival curve for patients with distal
esophageal (DE) and gastroesophageal junction (GEJ) adenocarcinomas
(P ¼ .16, log-rank test). B, Five-year disease-specific survival for patients
with distal esophageal (DE) and gastroesophageal junction (GEJ) adenocar-
cinomas (P ¼ .41, log-rank test).598 The Journal of Thoracic and Cardiovascular SuThe cause of adenocarcinoma of the GEJ is less clear, but
there is increasing evidence that it also follows a path from
intestinal metaplasia to dysplasia and cancer.1,7,8 It is well
established that intestinal metaplasia is a common patho-
logic finding when biopsy specimens are obtained at an
endoscopically normal-appearing GEJ, and in some patients
dysplasia and small cancers have been found confined to the
GEJ, confirming the link between intestinal metaplasia of
the cardia (CIM) and adenocarcinoma of the GEJ.8,9 It is
likely that in some patients CIM develops as a consequence
of Helicobacter pylori infection and pangastric intestinal
metaplasia, whereas in others with no intestinal metaplasia
in the antrum and no history of H pylori infection, CIM is
likely secondary to a reflux cause. Although CIM appears
to have a lower malignant potential than Barrett’s esopha-
gus, this lower malignant potential is offset by the greater
prevalence of CIM in the population.1,9
The GEJ remains a controversial area, with even the
normal mucosa at this site disputed.10-13 Furthermore, the
presumed location of the GEJ varies depending on whether
it is being viewed endoscopically, surgically, or pathologi-
cally. Most commonly, the GEJ is seen endoscopically,
and the accepted definition is the site where the proximal
limits of the gastric rugal folds in a nondistended stomach
meet the tubular esophagus. However, in patients with
a DE cancer, determining the precise location of the GEJ
can be difficult. This difficulty was illustrated in a recent
prospective randomized trial on esophageal and GEJ adeno-
carcinoma from The Netherlands, in which the authors noted
TABLE 5. Prevalence and site of recurrence (patients might have
more than 1 site of recurrence)
DE tumors GEJ tumors P value*
Surgical intervention alone n ¼ 245 n ¼ 170
Any recurrence 93 (38.0%) 60 (35.6%) .61
Site of recurrence
Locoregional 17 (6.9%) 12 (7.1%)
Distant nodes 28 (11.4%) 13 (7.6%)
Systemic 63 (25.7%) 42 (24.7%)
Liver 31 21
Lung 16 9
Bone 10 6
Brain 3 3
Carcinomatosis 2 5
Skin 2 1
Other 6 3
Neoadjuvant therapyþ
surgical intervention
n ¼ 56 n ¼ 38
Any recurrence* 31 (55.4%) 21 (55.3%) 1.0
Site of recurrence
Locoregional 4 (7.1%) 3 (7.9%)
Distant nodes 7 (12.5%) 2 (5.3%)
Systemic 21 (37.5%) 18 (47.4%)
DE, Distal esophageal; GEJ, gastroesophageal junction. *Two-sided Fisher’s exact
test.rgery c September 2009
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scopic tumor classification, which was used for the preoper-
ative stratification process, and the pathologic tumor
classification in the resected specimen.’’14 They reported
that frequently what the endoscopist labeled as a DE adeno-
carcinoma, the pathologist considered a GEJ tumor.
The difficulty with endoscopic determination of the GEJ
has also been shown in a recent autopsy study by Chandra-
soma and colleagues.15 In this study the authors found that
the reflux-damaged DE can become dilated, develop rugal
folds, and be lined by columnar mucosa, thereby mimicking
the proximal stomach. They used the histologic presence of
submucosal glands and the location of gastric oxyntic
mucosa to conclude that the true GEJ was as much as 2
cm distal to the endoscopically determined location. Given
the inaccuracy of the endoscopic determination of the
GEJ, Chandrasoma and colleagues proposed that GEJ
tumors should be classified based on the type of epithelium
at the epicenter of the tumor and at the distal margin of the
tumor rather than the perceived relationship of the epicenter
of the tumor to the endoscopically determined location of the
GEJ. Using this method, they found that 30 (83%) of 36
adenocarcinomas that were considered to be GEJ tumors
were in fact DE cancers.
Another problemwith trying to relate the epicenter of a tu-
mor with the location of the GEJ is that large tumors often
obscure the landmarks to the point that a clear determination
of whether a tumor is located in the DE or at the GEJ is not
possible, as was the case in 96 patients in this study. Given
the frequent discrepancy between the endoscopic and path-
ologic location of the GEJ and the problemwith large tumors
obscuring the commonly used landmarks, we wondered
whether an effort to distinguish between adenocarcinoma
of the DE and the GEJ was clinically necessary and under-
took a review of our experience with these tumors.We found
that although there were differences in symptoms, the
presence of intestinal metaplasia, and involvement in a sur-
veillance endoscopy program between patients with adeno-
carcinoma of the DE and those with adenocarcinoma of
the GEJ, there were no significant differences in the preva-
lence or location of nodal metastases, type of recurrence,
or overall or disease-specific survival in patients with these
tumors.
An important aspect of this study is that the majority of
patients (>95%) were treated similarly with an esophagec-
tomy, and most commonly, an en bloc resection was per-
formed. Other series typically include a high percentage of
total gastrectomies for GEJ adenocarcinoma, and this com-
promises assessment of the pattern and location of node
metastases. In the series by Siewert and associates,4 lower
mediastinal nodes were involved in 15.6% of patients. Sub-
carinal nodal involvement was not specified, likely because
most patients (82%) with GEJ tumors at their center were
treated with extended gastrectomy rather than esophagec-The Journal of Thoracic and Ctomy. In this study we compared the prevalence and pattern
of node metastases only in patients who had an en bloc re-
section with systematic mediastinal and upper abdominal
lymphadenectomy, and we were therefore able to defini-
tively compare the prevalence and distribution of lymph
node metastases in patients with DE or GEJ adenocarci-
nomas. We found that mediastinal nodal involvement was
present in 26% of DE adenocarcinomas and 25% of GEJ
adenocarcinomas, with the majority of involved nodes lo-
cated in the paraesophageal region for both tumor locations.
Furthermore, abdominal node involvement was present in
47% of DE adenocarcinomas and 52% of GEJ adenocarci-
nomas, with the majority of involved nodes located along
the lesser curvature for both tumor locations. Importantly,
when only patients with at least 1 involved node were con-
sidered (patients with N1 disease), we found that 47% of
patients with DE adenocarcinomas and 41% of patients
with GEJ adenocarcinomas had a positive mediastinal
node, and in 9% and 8%, respectively, this was the only
site of nodal involvement.
Given the high prevalence of mediastinal node involve-
ment with both DE and GEJ adenocarcinomas, it is clear
that a lower mediastinal node dissection needs to be included
in the surgical therapy for both of these tumors. This fact is
acknowledged in the study by Siewert and associates,4 who
routinely split the diaphragm and resect the lower mediasti-
nal nodes as part of a total gastrectomy for tumors at the
GEJ.16 Had this not been part of the operative strategy, it
is unlikely that they would have shown equivalent survival
for esophagectomy and total gastrectomy in patients with ad-
enocarcinomas located at the GEJ. The danger with recom-
mending gastrectomy for GEJ adenocarcinomas is that few
centers have the experience that Siewert and associates do,
and the tendency among low-volume centers is likely to be
to minimize the mediastinal dissection and perhaps compro-
mise on the esophageal resection margin. Although the fre-
quency of a positive proximal resection margin for patients
with GEJ tumors who had a total gastrectomy in the series by
Siewert and associates is not specified, the article indicates
that an R0 resection was only accomplished in 75% of pa-
tients.4 This is substantially lower than our R0 resection
rate of greater than 90% when esophagectomy was the
preferred resection technique. In keeping with concerns
regarding the proximal resection margin obtained when
a gastrectomy rather than an esophagectomy is performed
for GEJ adenocarcinoma, Barbour and coworkers17 from
the Memorial Sloan–Kettering cancer center recently re-
ported that survival was significantly improved when the
gross esophageal resection margin was greater than 3.8 cm
from the tumor in the fixed specimen (which translated to
5 cm in the native state). This was best accomplished with
an esophagectomy, and the authors noted significantly im-
proved survival in patients who had an esophagectomy for
GEJ adenocarcinomas compared with those who hadardiovascular Surgery c Volume 138, Number 3 599
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all Siewert types (I, II, and III), and it is likely that if the anal-
ysis had been restricted to only Siewert types I and II (ex-
cluding the subcardial or proximal gastric cancers), the
significance in favor of esophagectomy over gastrectomy
would have been even more striking.
We favor an en bloc resection in physiologically suitable
patients with tumors of the DE or GEJ and have reported
good survival and rare local recurrence with this procedure.
Previously, we retrospectively reviewed our experience with
transhiatal versus en bloc resection in patients with a DE or
GEJ T3 N1 adenocarcinoma and reported that survival was
significantly better with the en bloc procedure when there
were 8 or fewer involved nodes.18 Beyond 8 involved nodes,
survival was poor and independent of the type of resection.
Our retrospective results have recently been confirmed in
a randomized prospective trial of en bloc transthoracic
versus transhiatal esophagectomy for adenocarcinoma of
the DE.14 Subgroup analysis in this trial showed a statisti-
cally significant 20% improvement in survival for patients
who had an en bloc resection compared with those who
had a transhiatal esophagectomy when there were 1 to 8
involved nodes.
We have also shown that the benefit of an en bloc resection
remains evident even after neoadjuvant therapy. We evalu-
ated survival in patients with residual disease after neoadju-
vant therapy and reported a significant improvement in
survival for those patients with adenocarcinoma of the DE
or GEJ who had an en bloc compared with a transhiatal resec-
tion.19 The explanation for the improved survival after en bloc
esophagectomy is in part related to the improved local control
that the en bloc resection provides. However, there also seems
to be a direct benefit from the thorough lymphadenectomy
that accompanies an en bloc resection. Using pooled data
from 9 international esophageal cancer centers, we have
shown that the number of lymph nodes removed with an
esophagectomy is an independent predictor of survival and
that the likelihood of survival is maximized when a minimum
of 23 lymph nodes are resected.20 Similar findings supporting
the role for extended lymphadenectomy in patients with
esophageal cancer have been published by Altorki and col-
leagues21 and Schwarz and Smith.22 Even in node-negative
patients a positive effect on survival has been demonstrated
with a more extensive lymphadenectomy.23 These results
support the routine use of an en bloc esophagectomy in
patients with both GEJ and DE adenocarcinomas.
In the current study we have shown that the prevalence
and type of recurrence was similar for both GEJ and DE ad-
enocarcinomas. Most recurrences were systemic, with a low
rate of abdominal carcinomatosis for both tumor locations.
In the patients who had neoadjuvant therapy in this series,
we did not see a clear reduction in local–regional recurrence
rates, perhaps because of our frequent use of the en bloc pro-
cedure. Likewise, systemic disease was the predominant600 The Journal of Thoracic and Cardiovascular Surform of recurrence with and without neoadjuvant therapy.
Improved therapies to control systemic metastases with
this disease are critical to building on the improvements in
local control that have been achieved with the en bloc surgi-
cal technique. We found that overall and disease-specific
survival were similar for adenocarcinoma of the DE and
GEJ and showed that both tumors are effectively treated
with esophagectomy. Thus from a clinical standpoint, our
study and others suggest that efforts to preoperatively deter-
mine whether the tumor is a DE adenocarcinoma or a GEJ
adenocarcinoma are unnecessary.24
Our study is limited by the fact that it is retrospective,
although this limitation is minimized by the fact that all pa-
tients were treated in a single high-volume center by experi-
enced esophageal surgeons. Furthermore, the surgical
technique and our philosophy regarding treatment for these
tumors are standardized, with 100% of patients with adeno-
carcinoma of the DE and more than 95% of patients with ad-
enocarcinoma of the GEJ having an esophagectomy. Nearly
50% of patients in each group had an en bloc esophagec-
tomy, and this allowed us to accurately determine the prev-
alence and distribution of lymph node metastases for tumors
in each location.
Another limitation is that there were 96 (19%) patients
with tumors so large and bulky that we were unable to cate-
gorize them as DE or GEJ in origin. However, this under-
lines the problem with the Siewert classification system
and reflects the reality that we face as clinicians. By demon-
strating that it is not necessary to determine whether an ad-
enocarcinoma near the GEJ is a DE or a GEJ cancer, we
simplify the management of these patients and avoid the
ambiguity that is often present because of variable and indis-
tinct endoscopic landmarks and the presence of large tumors
that are not readily classifiable.
Lastly, a potential weakness is that we were unable to
compare the pathologic determination of the location of
the tumor with our endoscopic determination because our
pathologists did not assess tumor location at the time of
specimen resection in the operating room. However, a deter-
mination of the location of a tumor that can only be accu-
rately made on pathologic examination of the resected
specimen would not be clinically useful for guiding the
choice of therapy in these patients. Therefore we believe
that focusing our analysis on the preoperative endoscopic as-
sessment of tumor location was the most appropriate meth-
odology for this study.
In conclusion, we have shown that the clinically relevant
issues related to the therapy of adenocarcinoma of the GEJ
or DE, including the prevalence and distribution of node
metastases, the prevalence and type of recurrence, and over-
all and disease-specific survival, are similar for these tumors.
The high prevalence of nodal metastases in the lower medi-
astinum makes a lymphadenectomy in this region a critical
part of successful surgical therapy for both tumors andgery c September 2009
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There are inherent inaccuracies in trying to determine the
precise location of the GEJ and the relationship of the epi-
center of a cancer to the GEJ. Given these difficulties and
the lack of a significant difference in the biologic behavior
between adenocarcinoma of the DE and GEJ, we suggest
that efforts to determine the precise origin of the tumor are
not necessary and that an esophagectomy, preferably an en
bloc resection, is appropriate surgical therapy for adenocar-
cinoma in either location.
We thank Linda Chan from the University of Southern Califor-
nia for her dedicated support and advice regarding statistical
analysis and methodology in this article.
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Discussion
Dr Thomas W. Rice (Cleveland, Ohio). Confusion and contro-
versy surrounds the esophagogastric junction. I would like to thank
Dr Leers and her colleagues for presenting this most important
analysis of their experience with the surgical treatment of cancers
of the esophagogastric junction. It is reports such as this that will
shed light on this contentious transition area of the upper gastroin-
testinal tract, help end therapeutic disputes, and guide us in the
treatment of cancers arising in this borderland.
This 10-cm/4-inch segment of the DE and proximal stomach has
been classified into 3 areas by Dr Siewert and his colleagues. Im-
portantly, their classification is based on pathologic assessment
of the epicenter of the tumor, an easy thing to do in the quiet of
the pathology laboratory. However, if this information is to be clin-
ically important, it must be available before treatment in the living,
swallowing world of the esophagoscopy suite. Dr Leers and her
colleagues rightly determined Siewert type at initial endoscopy.
They point out the difficulty of defining the esophagogastric junc-
tion endoscopically but have rigorously attempted to type these
cancers in 613 patients. Not surprisingly, every sixth patient defied
classification. At first, I wondered how these missing data should
have been handled in the analysis, but it became evident that these
96 unclassifiable patients represented an interesting quasi–control
group for your analysis. Although it might require propensity scor-
ing, because these are typically larger tumors, it would strengthen
your argument if patients with unclassifiable tumors had a survival
similar to that of patients from either classifiable group.
My first question is this: Have you or will you add this group to
your analysis?
Dr DeMeester. Thanks, Tom. Yes, we actually did that. The
same thought struck us, so we plotted the Kaplan–Meier survival
for those patients, and it is identical. It actually falls right in be-
tween the 2 lines for DE and GEJ tumors. Therefore we looked
at that. There was some debate within our group as to whether it
was legitimate to include those patients because, as we said, we
could not really fit them into either the DE or GEJ group, and
whether their addition just muddied the waters was a concern.
Therefore the final decision was to leave them out. But it is certainly
an interesting point, and at least now in the discussion it will be ev-
ident to everybody that the survival for these unclassified tumors
falls right in between the lines for the other 2 groups.ardiovascular Surgery c Volume 138, Number 3 601
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tumor type increases from I to II to III, cancers have a higher T,
a higherN, a higherM, higher histologic grade, andmore cancer-pos-
itive nodes. Although your data only include two thirds of this classi-
fication schema, if you look carefully, type II cancers compared with
type I cancers have a significantly higher T, 7%more N1, and 4% of
cancers with 5 or more positive lymph nodes, and at 5 years, there is
a 7% difference in survival. You claim that these groups are similar,
but they are systematically slightly different, and these differences
might be masked to some extent by the group composition.
I have 2 questions. Have you considered the addition of histo-
logic grade, as has Siewert, that would allow for more equal group
comparisons? And to permit a fair comparison of these retrospec-
tive data, have you considered matching patients, such as with
propensity scores, allowing risk adjustment and therefore analysis
of comparable groups that differ only by the Siewert tumor type?
Dr DeMeester. It is an interesting issue. The debate about
whether tumor grade is important or not is really, I think, coming
to the forefront when you look at early tumors. Ell and colleagues
suggested that well-differentiated tumors should be treated differ-
ently than poorly differentiated tumors. In my own practice,
when you have a reasonably sized mass, it has not made a differ-
ence, and at this point, I do not factor tumor grade in when I do
endoscopic mucosal resection as therapy for these early tumors.
Therefore it is not clear that it is an important distinction, although
it is something to consider.
In terms of further forms of analysis, I think that we could
certainly do some type of matching, but I think the difference
that you are seeing is that patients who have intestinal metaplasia
in the esophagus (ie, Barrett’s esophagus) receive surveillance,
and that is why there is a slightly higher incidence of early tumors
in that group of patients because there is a number that receive sur-
veillance and are discovered, which is becoming a bigger number
every year. The gastroenterologists in particular have not ascribed
intestinal metaplasia limited to the GEJ as a premalignant condition
that should be followed, and increasingly, there is evidence now
that that is the precursor of adenocarcinoma of the GEJ. I personally
believe those patients should be followed as well, and maybe we
would discover some of these tumors before they present with dys-
phagia and more advanced tumors. Therefore I think the explana-
tion for more T4 disease and the more advanced stages with GEJ
tumors is they are not in a surveillance program in most circum-
stances. We could certainly try to do a more detailed matching of
the 2 groups, but I am of the belief that the more statistics you
have to use to prove something, the less likely it really is a signifi-
cant difference. It came out as no difference with very easy statis-
tics, and I believe that is the real situation.
Dr Rice. But your groups might not be completely comparable.
Dr DeMeester. I think they are perfectly comparable.
Dr Rice. We can agree to disagree.
Finally, in multivariable analysis Siewert and associates have
shown that Siewert tumor type is not a predictor of survival, as
you have found. Your analysis, however, does not include a multi-
variable analysis. Powerful support of your argument that type I
and type II tumors are similar would be gained if a multivariable
analysis of matched patients demonstrated that Siewert tumor
type was not a significant variable predicting outcome. My fourth602 The Journal of Thoracic and Cardiovascular Suquestion is this: Will you include this important multivariable anal-
ysis in your report?
Dr DeMeester. Well, again, we could try to look at that, but to
do a multivariable analysis, you have to have significant differences
on univariate analysis. There was no difference really in the lymph
node prevalence of metastases. There is no difference in survival by
means of Kaplan–Meier/log-rank analysis. Therefore, again,
although you and Dr Blackstone need to be commended, I think
if you need a lot of statistics to prove a point, then there are some
questions about how significant that point is. It was very clear
that these 2 groups came out together. We can certainly do that,
but, again, I do not see that we are going to change anything.
Dr Rice.Well, the way that would help you is if you prove that
T, N,M, G, and number of lymph nodes are very, very important, as
we all know.
Dr DeMeester. We know that, Tom. We know that. That has
been proved over and over.
Dr Rice. But then you show that there is no room left to tell us
that Siewert tumor type is significant, and you will help bury this
archaic and not helpful classification.
Thank you.
Dr DeMeester. Thanks. We can certainly consider it.
DrMark J. Krasna.(Towson, Md) Tom, I have just a few ques-
tions regarding lymph nodes. Your colleague did a great presenta-
tion. Surprisingly, though, the overall prevalence of lymph node
metastasis was roughly 50% in the chest and 50% in the abdomen.
Therefore one question is this: Can you explain the lower incidence
of lymph node involvement than seen in some of the other reported
series, where it approaches 75% to 85%? Was there a high use, for
instance, of neoadjuvant therapy in your series?
Dr DeMeester. No. Neoadjuvant therapy was 18% in each
group, and when we looked at node distribution and prevalence
of lymph nodes, it was only in the en bloc group without neoadju-
vant therapy so as not to confuse the issue of where nodes were and
so forth.
Dr Krasna. Second, just to follow up on that, I was impressed
that the celiac node involvement number was actually quite low.
It was only about 10% in one group and a little bit more in the other.
Is there an aversion in your group to include patients who have pos-
itive celiac nodes, or is that simply what your finding is at the time
of your en bloc resection? The reason I ask is this. As we have heard
from the proposed new staging system, celiac node involvement
will be like any other node involvement in the future, and if there
is an aversion to operate on such patients, there apparently is no
clear-cut evidence that that is correct. Therefore I am curious about
your philosophy.
Dr DeMeester. No, we have no aversion to that. In fact, we
published years ago that the presence of celiac node involvement
has absolutely no bearing on survival. If you look at celiac node
involvement in the context of the number of involved nodes, you
will find it is the number of involved nodes that predicts survival.
The celiac node itself is meaningless. Therefore I would prefer to
have 1 celiac node positive than to have 5 nonceliac nodes pos-
itive. I would take the first choice any day of the week. Therefore
it is the number of involved nodes and not the distribution that is
important. We have no qualms about taking out celiac nodal
disease.rgery c September 2009
